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Background: Prostate cancer (PCa) is a critical health burden, impacting the morbidity
and mortality of millions of men around the world. Most of the patients with PCa have
their disease at first sensitive to androgen deprivation treatments, but later they develop
resistance to therapy and eventually die of metastatic castration-resistant prostate cancer
(CRPC). Although the newly developed anti-androgen therapies are effectively alleviating
symptoms and prolonging lives of patients, there are still no curable treatments for
CRPC. Recently, statistical studies have shown that the chronic use of aspirin might
be significantly associated with better outcomes in PCa patients. Through this review,
we aim to identify the different proposed molecular mechanisms relating aspirin to the
pathobiology of PCa neoplasms, with a major focus on basic research done in this
context.
Methods: Articles were retrieved via online database searching of PubMed and
MEDLINE between 1946 and September 2016. Keywords and combinations related to
PCa and aspirin were used to perform the search. Abstracts of the articles were studied
by two independent reviewers and then data extraction was performed on the relevant
articles that met our review objectives.
Results: Aspirin, a non-steroidal anti-inflammatory drug (NSAID), affects the
proliferation, apoptosis, resistance and metastasis of PCa cell lines, through both
COX-dependent and COX-independent mechanisms. It also lowers levels of the PCa
diagnostic marker prostate specific antigen (PSA), suggesting that clinicians need to at
least be aware if their patients are using Aspirin chronically.
Conclusion: This review strongly warrants further consideration of the signaling
cascades activated by aspirin, which may lead to new knowledge that might be applied
to improve diagnosis, prognosis and treatment of PCa.
Keywords: prostate cancer, NSAIDs, aspirin, COX pathway, chemoprevention
INTRODUCTION
Prostate cancer (PCa) is the most prevalent solid tumor in men from industrialized nations and is
the second largest cancer-related killer (Center et al., 2012; Siegel et al., 2013). Age is a significant
risk factor for the disease. The incidence in USA jumps from 1 in 7,964 to 1 in 8 when comparing
men under 40 years of age with men older than 70, respectively (Siegel et al., 2013). Most of the
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patients with advanced PCa are initially sensitive to traditional
treatments of androgen ablation therapy. This is the mainstay
of treatment, and leads to the regression of PCa tumors (Suzuki
et al., 2000; Feldman and Feldman, 2001). However, with the
progression of the disease, PCa often develops resistance to
therapy and patients may eventually die of this metastatic
castration-resistant prostate cancer (mCRPC). As many as 50%
of PCas will progress from an androgen-dependent (AD) to a
hormone refractory state of disease, and will metastasize to bone
and pelvic lymph nodes (Thalmann et al., 1994).
There are still no curable treatments for CRPC (Karantanos
et al., 2013). Drugs such as abiraterone, enzalutamide and
TOK-001, bone-targeted therapies (such as bisphosphonates,
denosumab, and Radium-223), and immunotherapies all have
questionable efficacy (Chaturvedi and Garcia, 2014). Hence,
novel treatment strategies are a necessity to improve the quality
and span of life for PCa patients. Understanding the underlying
mechanisms behind progression of PCa to CRPC and its
metastasis is crucial in defining new therapeutic targets and
prophylactic therapies for this type of cancer.
While the role of non-steroidal anti-inflammatory drugs
(NSAIDs) in preventing colorectal cancer has been well-
established (Muscat et al., 1994), numerous epidemiological
studies have shown that they are protective against other
cancers as well (Baron and Sandler, 2000; Cha and DuBois,
2007). One study reported nearly a 63% drop in the relative
risk for colon cancer, 39% for breast cancer, 36% for lung
cancer, and 39% for PCa with the increasing intake of NSAIDs
(mainly aspirin or ibuprofen; Harris et al., 2005). One meta-
analysis looked specifically at the association between aspirin
and PCa, combining the results of 39 studies (20 case-control
and 19 cohort studies; Liu et al., 2014). It was found that
aspirin use was significantly associated with lower PCa incidence
(OR = 0.92, 95% CI = 0.87–0.97) and lower PCa-specific
mortality (HR = 0.86, 95% CI = 0.78–0.96). While evidence
suggests a protective effect of aspirin, the processes underlying
this remain unclear.
The aim of this paper is to review some of the proposed
mechanisms relating aspirin to the pathobiology of PCa
neoplasms, with a main focus on the basic science research done
in this context.
DECREASED PSA LEVELS IN CHRONIC
ASPIRIN USERS AMONG PROSTATE
CANCER PATIENTS
The majority of PCa patients first learn they might have the
disease through a blood test that looks for increased or rising
levels of PSA protein (Hamilton et al., 2008), produced by
luminal cells in the prostate (Feldman and Feldman, 2001). In
these settings, PSA can indicate the presence or recurrence of
PCa. The concern is that drugs that artificially lower PSA levels
might mask this marker, which normally flags the development of
a prostate neoplasm. One study analyzed PSA levels in a cohort
of over 1,000 men and found that PSA levels in the sample of
men taking aspirin were nearly 10% lower than a control sample
not taking aspirin (Hamilton et al., 2008). Researchers question
whether this decrease in PSA is artificial or whether it might be
a direct result of anti-tumorigenic properties of aspirin. Evidence
points in both directions.
Multiple epidemiological studies have reported an increase in
high-grade PCa (HGPCa) in aspirin users (Bosetti et al., 2012;
Olivan et al., 2015). One suggested explanation found in the
literature is that aspirin and other NSAIDs lower PSA levels, but
is not itself anti-tumorigenic (Berg et al., 2009; Schroder et al.,
2009). If true, this would likely delay diagnosis of the disease,
allowing it to progress unnoticed. Alternatively, it was also
suggested that these drugs might relieve cancer-associated pain
that normally motivates patients to investigate their symptoms
earlier on. In contrast, it must also be noted that other studies
show decreased levels of HGPCa in chronic aspirin users (Brasky
et al., 2010; Dhillon et al., 2011). More conclusive research needs
to be conducted to determine the mechanism by which aspirin
decreases PSA: whether this is a by-product of the drug’s anti-
tumorigenic properties or truly a masking effect. Nonetheless,
physicians should be weary of the accuracy of the PSA blood test
in patients taking aspirin chronically.
ASPIRIN AND THE COX PATHWAY IN
PROSTATE CANCER
NSAIDs inhibit the metabolism of arachidonic acid by blocking
the cyclooxygenases (COXs) pathway and the prostaglandins
(PGs) synthase pathway, thus suppressing PG synthesis and
inflammation (Majima et al., 2003; Figure 1). COXs are key
enzymes in prostanoid synthesis, existing in two isoforms: COX1
and COX2. COX1, referred to as “constitutive isoform,” is
expressed in several tissues under basal conditions. COX2 is
believed to be undetectable in normal human tissues, but can
be induced by mitogens, cytokines, and tumor promoters under
various, mainly pathological condition. It is thus referred to
as “inducible isoform” (Katori and Majima, 2000; Gupta and
Dubois, 2001; Subbaramaiah and Dannenberg, 2003). COX2
activation hence promotes enhanced PGs synthesis in both
inflamed and neoplastic tissues (Bennett, 1986; Rigas et al., 1993).
Aspirin is unique in that it irreversibly blocks both COX1
and COX2 activities through acetylation of significant enzyme
serine residues. Ergo, new COX activity can only be achieved
following aspirin treatment through de novo synthesis of COX.
The main mechanism by which NSAIDs are thought to prevent
the growth of neoplasms is the blocking of COX2 activity (Thun
et al., 2002), though studies have shown that NSAIDs like
aspirin have anticancer effects through both COX-dependent and
independent cascades (Grosch et al., 2006; Alfonso et al., 2014).
Several studies have demonstrated higher expression of COX2
in PCa tumor tissues than in benign prostate tissues (Gupta et al.,
2000). It has been shown that both LNCaP and PC3 PCa cell
lines express COX2. High COX2 expression in PCa cells has also
been associated with poor prognosis (Khor et al., 2007). This has
further corroborated the suggestion that NSAIDs could play a
role in reducing PCa risk specifically through inhibiting the COX
pathway.
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FIGURE 1 | Schematic diagram showing the mechanism of action of NSAIDs like aspirin in inhibiting the metabolism of arachidonic acid by blockade
of the cyclooxygenases (COX) pathway and the prostaglandins (PG) synthase pathway, thus suppressing PGs synthesis. Aspirin also works by
upregulating EP3, an inhibitory G-protein-coupled receptor of the prostaglandin PGE2.
In vivo, anti-inflammatory doses of aspirin (a daily dose of
>2,000 mg) do bring systemic concentrations high enough to
inhibit both COX1 and COX2. However, in nucleated cells,
due to de novo synthesis, inhibition can only be prolonged
with repeated daily dosing (Thun et al., 2012). It has been
suggested in that same paper that aspirin in lower doses might
still effectively inhibit COX2 due to partial dependence of COX2
expression in monocytes on activated platelets. Consequently,
aspirin permanently inactivates COX in platelets, thus indirectly
inhibits COX2 expression (Thun et al., 2012).
The blockage of COX prevents the production of downstream
PG products, known as prostanoids, such as TXA2, PGI2, PGE2,
PGF2α, and PGD2. These prostanoids have roles in decreasing
apoptosis and increasing cellular proliferation (Thun et al., 2012).
One PCa-specific study reported that aspirin-treated LNCaP and
PC3 PCa cells had the same proportion of dead cells as non-
treated cells, signifying that aspirin might not induce apoptosis
but instead suppresses proliferation (Olivan et al., 2015). The
literature is not conclusive on this, however. In addition, this
paper reported decreased colony formation and significant
inhibition of invasion and migration capacities in aspirin-treated
cells (PC3 cells in particular) with higher effects when aspirin is
combined with simvastatin, a cholesterol-lowering drug (Olivan
et al., 2015).
Among the five PGs that have been identified in the COX
pathway, PGE2 is the most common and ubiquitously produced
PG, contributing to tumorigenesis via cell proliferation induction
(Tjandrawinata et al., 1997), angiogenesis (Wang and Klein,
2007; Jain et al., 2008), invasion (Sheng et al., 2001; Buchanan
et al., 2003), and metastasis (Konturek et al., 2005; Fulton et al.,
2006). PGE2 levels are 10-fold higher in human malignant
PCa tissues than in benign prostatic tissues (Chaudry et al.,
1994). PGE2 works through EP1, EP2, EP3, and EP4, four
G-protein coupled receptors (Kashiwagi et al., 2013). Human
prostate epithelial cells express EP2 and EP4 receptors, while
EP1 and EP3 receptor expression in these cells is not detected
(Wang and Klein, 2007). EP3 is distinct from EP2 and EP4
in that it is not a stimulatory but instead an inhibitory G-
protein. Thus, EP3 decreases levels of the secondary messenger
cAMP when activated. A study by Kashiwagi et al. reported
that aspirin decreases Androgen Receptor (AR) mRNA and
protein levels in dose-and time-dependent manners (Kashiwagi
et al., 2013), which is thought to be related to the proliferation
of PCa. Interestingly, the same study reported upregulation of
EP3 expression and a consequent downregulation of AR and
EP2 expression in PCa cell lines upon aspirin treatment. This
domino effect was confirmed using both pharmacological and
knockdownmethods. The results are supported by another study
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that found that EP3 signaling inhibits the NF-κB pathway (Wang
et al., 2010), which decreases AR expression levels in PCa cells
(Zhang et al., 2009).
This was not the first paper to claim this connection to the NF-
kB pathway. Lloyd et al. previously showed that aspirin inhibits
NF-κB, resulting in diminished urokinase-type plasminogen
activator (uPA) secretion—one of the crucial molecules involved
in cancer metastasis—from the highly invasive human PC3 PCa
cells (Lloyd et al., 2003). The inhibition of COX in platelets
might also be significant, since experimental evidence has shown
that platelets are significant in cancer metastasis through the
blood (Labelle et al., 2011; Dudeja et al., 2012). This effect is
mediated through their ability to aggregate and allow cancer cells
to escape immune detection as well as the pro-angiogenic factors,
such as VEGF, that they release (Usman et al., 2015). Thus, the
EP3 receptor might represent a potential molecular target for
developing therapy in PCa.
ASPIRIN AND COX-INDEPENDENT
REGULATION OF THE CELL CYCLE IN
PROSTATE CANCER
Aspirin might influence regulation of the cell cycle, which is
dependent on a family of proteins called cyclins and another
group of protein kinases called cyclin-dependent kinases (CDKs).
When combined with statins in treatment, aspirin was shown
to decrease proliferation of LNCaP cells with a reduction in
cyclin D1 levels—which modulates cell cycle progression (Olivan
et al., 2015). Aspirin, on its own, was shown to cause ubiquitin-
dependent degradation of cyclin D1 in colorectral cancer cells
(Thoms et al., 2007). Further research is needed to deduce
whether aspirin can instigate the same mechanism in PCa cells
in the absence of statins, since on their own, statins were also
shown to be associated with low expression of cyclin D1 in a
breast cancer trial (Feldt et al., 2015).
Another proposed mechanism of control—as suggested by
epidemiological studies in colorectal cancer patients (Seiler, 2003;
Laukaitis and Gerner, 2011)—is the induction of polyamine
catabolism and subsequent regulation of cell proliferation and
cancer progression (Arisan et al., 2014). Polyamines are small
cationic molecules, formed from the decarboxylation products of
ornithine and S-adenosyl-methionine. They are present in high
concentrations in rapidly dividing tumor cells (Agostinelli et al.,
2010). Although intracellular levels of polyamines are elevated in
normal prostate gland (Karr et al., 1991), abnormal regulation
of their metabolism results in rapid cell proliferation and PCa
progression (Arisan et al., 2014). In fact, when PCa cells were
treated with CDK inhibitors purvalanol and roscovitine, which
induce apoptosis by promoting cell cycle arrest in cancer cells,
upregulation of polyamine catabolic enzymes (SSAT, SMO, and
PAO) was induced. This caused the depletion of intracellular
polyamine levels (Arisan et al., 2014). In the same study, silencing
of SSAT prevented CDK inhibitors-induced apoptotic cell death
in PCa cells (Arisan et al., 2014). Accordingly, aspirin has been
recognized as an inducer of SSAT by allowing NF-κB binding
on the Sat1 gene (Babbar et al., 2006). However, another study
showed that treating LNCaP PCa cells with aspirin decreased
induced SSAT activity in these cells (Li et al., 2016). Authors
of this study concluded that SSAT and its related polyamine
metabolismmay play a significant role in the susceptibility of PCa
to aspirin therapy (Li et al., 2016). The potential relevance of these
mechanisms needs to be further explored, especially using in vivo
trials and feasible, non-toxic doses of aspirin.
One study found that aspirin promotes “tumor necrosis
factor-related apoptosis inducing ligand” (TRAIL)-induced
apoptosis in both androgen-dependent LNCaP cells and
other LNCaP derived cells (C4, C4-2, and C4-2B), which
represent CRPC, through decreased survivin protein—a versatile
modulator of cell division and apoptosis in cancer (Altieri,
2003)—expression in these cells (Yoo and Lee, 2007).
And finally, researchers have also evaluated the effect of
new nitric oxide (NO) donating NSAIDs, including NO-
aspirin and NO-ibuprofen, on LNCaP and PC3 PCa cell
lines. They found these drugs to be potent inhibitors of
proliferation and inducers of apoptosis via enhanced caspase-
3 expression (Royle et al., 2004). One reason for the
importance of those novel NSAIDs over classical ones lies
in the presence of NO, which when endogenous, contributes
to the action of immune cells against foreign pathogens
and tumor cells. NO was additionally suggested to play a
role in the modulation of cell death by apoptosis, though
this effect depends on a multitude of factors, including
the concentration of NO and the cell type (Wallace and
Soldato, 2003). Interestingly, NO-aspirin had been shown to be
much more potent, even at lower concentrations, at inducing
apoptosis and inhibiting proliferation in those PCa cells than
conventional aspirin (Royle et al., 2004). In accordance, NO-
aspirin inhibited proliferation of PC3 and DU145 PCa cells
through blockingWnt/β-catenin signaling in those cells (Lu et al.,
2009).
Other studies have implicated the lipoxygenase (LO) pathway
of arachidonic acid metabolism in the progression of PCa.
Yang et al. showed that LO products, including 12-HETE,
were significantly higher in malignant prostate tissue than
non-malignant tissue. The role of an NSAID like aspirin
in this process is unclear (Yang et al., 2012). While one
might intuitively warn that the inhibition of COX redirects
arachidonic acid to the LO pathway, the evidence in the
literature is not conclusive. Gray et al. looked at COX and
LO activity in whole blood, noting that the blocking of COX
was not actually associated with an increase in LO products.
Furthermore, they reported that NO-aspirin even reduced LO
activity, a notion supported by other publications as well
(Gray et al., 2002). Brunn et al. for instance, reported that
endogenously released NO inhibits the production of 5-LO
metabolites in macrophages (Brunn et al., 1997). However, these
precise mechanisms of NO-aspirin still remain the subject of
investigation.
Thus, with the failure of androgen ablation therapies and
emergence of hormone-refractory states in PCa, enhancing
tumor cell death via facilitating apoptosis of cancer cells using
aspirin may be an effective promising chemopreventive therapy
for the disease in the future.
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ASPIRIN AND COX-INDEPENDENT
REGULATION OF METASTASIS OF
PROSTATE CANCER CELLS
Aspirin treatment has been associated with decreased migration
of PCa cell lines and increased levels of α2 integrin (Olivan et al.,
2015), which may be a metastasis suppressor as suggested by
Ramirez et al. (2011). These results are controversial, however,
as other studies reported conflicting data. Other literature
found that the expression of integrin α2β1 actually induces
PCa metastasis to the bone (Hall et al., 2008; Van Slambrouck
et al., 2009; Sottnik et al., 2013). These studies suggest that the
expression of this protein is in fact correlated with the different
stages of cancer progression (Hall et al., 2008; Van Slambrouck
et al., 2009; Mitchell et al., 2010). This might be the cause of
reported higher levels of HGPCa in patients treated chronically
with aspirin (Olivan et al., 2015); however, further research is
needed to clarify the role of integrins in PCa tumors and whether
they can be a molecular target for therapy.
It has been demonstrated that cell migration, and the
process of cancer metastasis, is regulated or influenced by
different molecular mechanisms. Another mechanism explored
specifically in regards to PCa concerns p75NTR, a member of
the tumor necrosis factor (TNF) receptor superfamily and tumor
suppressor highly expressed in normal prostate epithelial cells
(Chao, 1994). This high expression diminishes as the tumor
progresses (Pflug et al., 1992). Reports have shown that NSAIDs
like aspirin induce p75NTR expression through the p38 mitogen-
activated protein kinase (MAPK) pathway (Wynne and Djakiew,
2010). Correlating with the induction of p75NTR by NSAIDs is
the induction of Nag-1, a member of the TGF-B superfamily that
inhibits cell migration, possibly through blocking the activity of
uPA, and matrix metalloproteinases MMP2 and MMP9 (Wynne
and Djakiew, 2010). Thus, Wynne and Djakiew et al. proposed
that NSAID suppression of cell migration might be mediated by
Nag-1 induction, downstream of p75NTR.
THE EFFECT OF ASPIRIN ON
CHEMOTHERAPY IN PROSTATE CANCER
Aspirin may promote resistance to treatment in PCa in three
different mechanisms. First, many chemotherapeutic agents
work by targeting rapidly-dividing cells, thus decreased cellular
proliferation—as was shown to be an effect of aspirin on PCa
cells—might decrease the efficacy of these anticancer treatments.
Second, one study outlined how aspirin might produce
resistance against chemotherapy by looking at how the drug
affects P-glycoprotein (P-gp) expression (Rotem et al., 2000). It
was found that aspirin and similar drugs induce protein kinase
C (Zhu et al., 1999; Zimmermann et al., 2000), which enhances
the activity of a nuclear factor for IL-6 expression (Trautwein
et al., 1993; Combates et al., 1997). This consequently increases
the activity of the MDR1 promoter (Combates et al., 1994).
MDR1 encodes for an eﬄux pump called P-gp, which removes
a number of anticancer drugs from the cell, thereby causing the
chemotherapy agent to be ineffective at normal concentrations.
Rotem et al. concluded that although aspirin reduces cellular
proliferation in all 3 PCa cell lines studied (DU-145, PC-3, and
LNCaP), it induces a three-fold increase in the percentage of
cells expressing P-gp in LNCaP cell lines on the other hand
(Rotem et al., 2000). This expression of P-gp was reversible, only
persisting around 3 days, implying that it was not mediated by
changes at the genetic level (Rotem et al., 2000).
Third, it has been noted that aspirin causes cells to
become more thermotolerant by increasing heat shock protein
(HSP)-70 expression in these cells (Amici et al., 1995). The
administration of this drug might thus also interfere with
hyperthermic treatment, which is commonly used in conjunction
with chemotherapy or radiotherapy to enhance the effectiveness
of these forms of treatment.
CONCLUSION AND PERSPECTIVES
While large epidemiological studies have significantly shown
an inverse correlation between aspirin intake and cancers like
PCa, tests and assays using cell lines have revealed desirable and
undesirable outcomes that need to be explored more thoroughly.
It is thus clear that there are many reasons why clinicians need
to at least be aware if their patients with PCa are taking aspirin.
Whether or not aspirin can be used as an adjuvant to therapy
TABLE 1 | Proposed molecular mechanisms relating aspirin use in
prostate cancer.
Mechanism of Action References
Cancer
detection
Decreases PSA mRNA and protein levels Kashiwagi et al.,
2013
Regulation of
proliferation/
apoptosis
Inhibition of SSAT Li et al., 2016
Reduction in cyclin D1 Olivan et al., 2015
Decreases AR, upregulation of EP3 and
downregulation of EP2
Kashiwagi et al.,
2013
Blocks Wnt/B-catenin signaling Lu et al., 2009
Decreases survivin expression,
TRAIL-induced apoptosis
Yoo and Lee, 2007
Enhances caspase 3 expression Royle et al., 2004
Inhibition of NF-κB pathway and decrease
in AR expression
Lloyd et al., 2003
Regulation of
metastasis
Increases a2-integrin expression Olivan et al., 2015
Inhibition of NK-kB pathway and decrease
in uPA expression
Lloyd et al., 2003
Induction of p75NTR through MAPK
pathway and Nag-1
Wynne and
Djakiew, 2010
Resistance to
treatment
Increases expression of MDR1 Rotem et al., 2000
Increases HSP-70 expression Amici et al., 1995
SSAT, spermidine/spermine N(1)-acetyltransferase; AR, androgen receptor; EP3, E-
type prostaglandin receptor 3; EP2, E-type prostaglandin receptor 2; TRAIL, tumor
necrosis factor-related apoptosis inducing ligand; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; uPA, urokinase-type plasminogen activator;
p75NTR, p75 neurotrophin receptor; MAPK, mitogen-activated protein kinase; Nag-1,
N-acetylglucosamine-1; MDR1, multidrug resistance protein 1; HSP-70, heat shock
protein 70.
Frontiers in Pharmacology | www.frontiersin.org 5 March 2017 | Volume 8 | Article 145
Bilani et al. Molecular Mechanisms of Aspirin in Prostate Cancer
for PCa is yet undecided. This review strongly warrants further
consideration of the signaling cascades activated by the aspirin
(Table 1), which may lead to new knowledge that might be
applied to improve the diagnosis, prognosis and treatment of PCa
(Figure 1).
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